Trials / Withdrawn
WithdrawnNCT01309074
Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Rush University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to compare the safety \& efficacy of sertraline (up to a dose of 200mg/day) \& pregabalin (up to a dose of 300mg/day) for the treatment of symptoms of anxiety in patients with epilepsy.
Detailed description
Patients with epilepsy will be treated with either sertraline (up to a dose of 200mg/day) or pregabalin (up to a dose of 300mg/day) for the treatment of symptoms of anxiety. Outcome measures will include changes in the anxiety severity scales.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin-Lyrica | Pregabalin in a dose up to 300mg/day in BID dosing. |
| DRUG | Sertraline | Sertraline in a dose up to 200mg/day in BID dosing. |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2011-03-04
- Last updated
- 2023-02-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01309074. Inclusion in this directory is not an endorsement.